Strategic growth advisory
Understanding the potential offered by the EU framework for elective care treatment for a serious illness health insurance company
An EU-based, critical illness insurer
Provide full data and interpretation of the recent EU health Directive on elective cross-border treatment: Can it provide an opportunity for a new product or service?
The client wished to understand the legislation and the complex real-life mechanics of a new EU Directive on elective cross-border health treatment. The scope was restricted to the Polish-German cross border health traffic. Was there a possiblility to use this to redcue claims and/or to create a product around this?
MGG tapped multiple primary and secondary sources - eg all the EU reports on this over 5 years, interviews with the key info points in the 2 countries and other benchmark service companies plus an assessment of all the info provided by the countries - to understand and assess the EU Directive and its rules.
The client decided was advised NOT to commercialise the Directive as insurers were prohibited from reimbursement and the patient flows were too low.